GSK, formerly GlaxoSmithKline, traces its roots to a series of mergers spanning more than a century, with the modern entity formed in 2000 through the combination of Glaxo Wellcome and SmithKline Beecham. Headquartered in London, it is one of the largest pharmaceutical and biotech companies in the world by revenue, with operations across vaccines, specialty medicines, and general medicines.
A significant structural inflection came in 2022, when GSK demerged its consumer healthcare division, spinning it out as Haleon. The separation was designed to sharpen GSK's focus on biopharma, concentrating resources on infectious diseases, HIV, oncology, immunology, and respiratory conditions. The Haleon demerger was one of the largest such transactions in European corporate history at the time.
GSK's pipeline and commercial portfolio reflect a company that has repositioned itself around science-led speciality and rare-disease medicines rather than high-volume primary care products. Its vaccines business, which includes treatments for shingles and respiratory syncytial virus, represents a meaningful share of revenues and distinguishes it from peers with thinner immunisation portfolios.
For operators and founders in health tech and biotech, GSK is worth watching as a bellwether for how large incumbents integrate external innovation. The company has historically used partnerships, licensing agreements, and venture arms to access early-stage science, making it a relevant counterparty for scale-up businesses seeking commercial or development routes to market. Its post-demerger strategic clarity also offers a case study in how listed pharmaceutical groups manage portfolio focus under sustained investor scrutiny.
